GSK's Oncology Ventures Spark Hope Amid Growing Cancer Challenge

GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight decline in total income. The company is set to address rising cancer burdens in India by launching innovative oncology treatments, Jemperli and Zejula, fulfilling critical medical needs.

GlaxoSmithKline Pharmaceuticals reported a 12 percent increase in net profit for the June quarter, reaching Rs 279 crore, compared to Rs 249 crore in the same period last year. Despite a slight decline in total income to Rs 849 crore from Rs 850 crore, the drug firm plans to launch innovative oncology drugs in India.

The company announced its upcoming launch of two key oncology assets, Jemperli and Zejula, aimed at tackling a critical unmet need amid a rising cancer burden and limited access to advanced therapies in India. These launches represent a significant step forward in addressing the healthcare needs of the local population.

Jemperli, used for second-line dMMR endometrial cancer, and Zejula, a PARP inhibitor for ovarian cancer, are set to enter the Indian market, offering new hope to patients with limited treatment options. Shares of the company were trading 8.22 percent down at Rs 2,898.40 on BSE.

(With inputs from agencies.)